Healthcare
Halozyme Therapeutics (HALO)
Halozyme Therapeutics stock analysis and opportunity scoring
$121.84
As of Oct 16
↑ +0.27%
Halozyme Therapeutics (HALO) at a glance
Halozyme Therapeutics (HALO) is a publicly traded company in the Healthcare - Biotechnology sector tracked by MKD Intelligence.
HALO last traded at $121.84 up 0.27% on the session as of 2026-10-16.
MKD Intelligence assigns HALO a composite opportunity score of 71 out of 100, indicating favourable conditions across trend, momentum and volume factors.
The risk score for HALO is 43 out of 100 (moderate), where a higher number means greater expected volatility.
Healthcare sector comparison
HALO has a composite opportunity score of 71/100, above the 60.5/100 average across 84 tracked Healthcare stocks. RMD leads the sector at 78/100.
Price History
High
$121.84
Low
$106.94
Period
Oct 16 - Sep 18 (21d)
Hover for details • Scroll to zoom • Drag to pan • Double-click to reset
Recent News
No recent news available.
Upcoming Events
Data as of Oct 19
This platform provides market intelligence and educational information only. It does not constitute financial advice, and no information presented should be interpreted as a recommendation to buy, sell, or hold any security. Past performance and historical patterns do not guarantee future results.